Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: Efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïeve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. ESMO 2017 Congress; abstract LBA5.
Combinatie JAK-remmer en anti-PD-1 bij gemetastaseerd NSCLC
sep 2024 | Immuuntherapie, Longoncologie